Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RO 6864018

Next Previous
Search
Drug Profile

RO 6864018

Alternative Names: RO-6864018

Latest Information Update: 28 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 28 Sep 2021 Development discontinued for Phase-II for Hepatitis B (Treatment-experienced) in Malaysia, Taiwan, Singapore, South Korea, Hong Kong, New Zealand (PO, Capsule) before September 2021 (Roche pipeline, September 2021)
  • 03 Nov 2017 Roche completes a phase II trial in Hepatitis B (Treatment-experienced) in Hong Kong, South Korea, Malaysia, New Zealand, Singapore and Taiwan (NCT02391805)
  • 11 Nov 2016 Adverse events, pharmacodynamic and pharmacokinetics data from a phase I trial in Hepatitis B presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top